The federal government re-ignited a controversial proposal to give generic drug makers the power to unilaterally update product labels to reflect new safety information, a proposal that drew criticism ...
In the lengthy legal back-and-forth over the heart drug Coreg, GlaxoSmithKline has scored another victory against generic rival Teva. The decision could have far-reaching implications for the generics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback